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October 2018 Abstracts S981than TKI alone. We observed that VEGFR-2 was expressed at relatively
high levels in HCC827-GR than other cell line without METamp, and
VEGF pathway inhibition by bevacizumab resulted in decreased phos-
pho-c-Met in HCC827-GR cell lines. This result provided in vitro evi-
dence that bevacizumab can reduce MET pathway activation.
Conclusion: This study provided basic knowledge and evidence for
patients harboring concomitant EGFR and de novo MET amplification
who may obtain favorable response to combinatorial treatment of TKI
and bevacizumab. Encouraging antitumor activity of TKI+bevacizumab
support further development of this combination for patients with
advanced NSCLC and other solid tumors. Keywords: EGFR, de novo
MET, bevacizumab
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Afatinib in Lung Adenocarcinoma Harboring de novo
EGFR Exon 20 Insertions.M. Costa,1 J. Lewgoy2 1Oncology, Oswaldo Cruz Hospital, Sao Paulo/BR,
2Oncology, Hospital Do Câncer Mãe de Deus, Porto Alegre/BR
Background: NSCLC, particularly adenocarcinoma, has been suc-
cessfully treated with upfront targeted therapies according to
respective oncogenic mutations in a tailor-made model. EGFR-TK
inhibitors (TKi) have exhibited major responses, improving PFS, RR
and even mOS (a subset treated with afatinib). This drug has
emerged as the best option for those with uncommon mutations, but
until now is broadly unknown its action in exon 20 mutations, which
accounts for nearly 3% of all and, classically, is associated to worse
response to 1st-generation TKi. Method: Here, in this retrospective
analysis, is reported the past medical history and clinical outcomes
of two patients who presented with de novo EGFR exon 20 in-
sertions: D770_N771insSVD and Ser768_Asp770dup. The patient
were treated in two differents Cancer Centers in Brazil and the
mutations were identified with Next Generation Sequencing (NGS) by
Illumina HiSeqs of Foundation Medicine (FM) and the other by a
local certified laboratory using Ion Torrent-PGM Thermo Fischer
v5.0. Analysis were performed in tissue samples extracted from
FFPE. The follow-up was obtained from electronic charts. Result:
Patient 1: never-smoker 66 y/o lady, without comorbidities, pre-
sented 12 mo ago with dry cough, thoracic pain and -10% of weight.
CT scan revealed extensive ground-glass infiltration area and mul-
tiple bilateral pulmonary nodules. Lung biopsy pointed out a mod.
differentiated adenocarcinoma of predominantly lepidic pattern (IHC:
AE1/2+, CK20-, CK7+, Napsin A+, TTF1+). With this, rtPCR (Cobas
Mu test v.2) detected an exon 20 insertion, thus ineligible to upfront
EGFR-TKi. However, was chosen to re-analyze it using NGS (FM).
After a TAT of only 2 weeks, we retrieved the result which showed
a poorly described mutation: EGFR exon 20 insertion
D770_N771insSVD. Afatinib 30mg/day was started and, only three
days after the initiation, the patient decreased the dry cough and
fatigue. CT scans showed stable disease after 45 days of continuous
use. Patient 2 had a more extensive past medical history: 1L chemo,
followed by nivolumab and docetaxel. Lastly, NGS revealed an un-
common EGFR exon 20 insertion (Ser768_Asp770dup). Rapid clinical
improvement was observed (less fatigue and dyspneia), but occured
liver progression in the first control, 4w after initiation. Conclusion:
This study confirms that rare mutations have been increasingly seen
due to the employment of improved sensitivity genetic techniques,
like NGS. Furthermore, reveals two rare examples of rapid clinical
response to afatinib in patients harboring EGFR exon 20 insertions.Finally, despite it could be an option for management of this
broadly unknown situation, it suggests caution because of the
short-lasting benefit in some. Keywords: exon 20 insertions, EGFR,
Afatinib
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Background: Lung cancer remains the leading cause of cancer-related
death worldwide. Though most patients with EGFR activating muta-
tions are sensitive to EGFR tyrosine kinase inhibitors (TKIs), tumors
will inevitably acquire resistance to first generation EGFR TKIs. EGFR
T790M mutation and cMET amplification are common mechanisms.
Further study is needed to explore unknown genomic alterations
contributing to drug resistance. Method: In the screening period of
ASTRIS (D5160C00022) study of single center, tumor and blood sam-
ples from 69 stage ⅢB-Ⅳ NSCLC patients defined as acquired resis-
tance to first generation EGFR TKIs (Gefitinib, Elortinib or Ecotinib)
were collected. The cobas® and Droplet digital PCR (ddPCR) were used
to detect T790M mutations in tumor samples and plasma ctDNA. cMET
amplification were evaluated by Fluorescence in situ Hybridization
(FISH). Exome sequencing were performed in four T790M wildtype/
cMET unamplified samples. Result: The T790M mutation rate of FFPE
tissue cobas, plasma cobas and plasma ddPCR testing were 54.5%,
21.3% and 30.4% respectively. Taking all testing methods into account,
the T790M positive rate was 52.2%. In 21 samples which tumor re-
biopsy was performed, 14 were T790M positive (66.7%). cMET
amplification were identified in 3 out of 7 T790M negative samples.
Exome sequencing in 4 T790M wildtype/cMET unamplified samples
and paired white blood cells identified a cohort of candidate key
mutated genes including BRAF, FGFR1, PAK1, PCNT, PEBP4 and SOX3.
Conclusion: EGFR T790M mutation and cMET amplification are main
mechanisms leading to EGFR TKI resistant in lung adenocarcinoma.
These key mutated genes identified in the present study would need
further functional study validation. Keywords: exome sequencing,
cMET, T790M
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Background: The recommended starting dose of afatinib is 40mg od
with 20mg, 30mg and 50mg tablets available for dose adjustment.
Method: This is a retrospective observational study of starting dose,
dose adjustment and optimal dose of first-line afatinib in patients with
S982 Journal of Thoracic Oncology Vol. 13 No. 10SEGFR mutant advanced non-small cell lung cancer in University
Malaya Medical Center from 1st December 2014 to 30th April 2018.
Result: Of 22 patients on first-line afatinib, the starting dose was 40 mg
od in 12 patients and 30 mg od in 10 patients (Figure 1). Among the 12
patients started on afatinib 40mg od, 4 (33.3%) did not require dose
adjustment, 4 (33.3%) needed dose reduction to 30mg od, 2 (16.7%)
needed dose reduction to 20mg od, and 2 (16.7%) had dose escalation
to 50mg od. Among 10 patients started on afatinib 30mg od, 6 (60%)
did not require dose adjustment, 1 (10%) needed dose reduction to
25mg od and 3 (30%) had dose escalation to 40mg od. Dose reduction
was to reduce the cost of treatment in 1 patient and to reduce drug-
related side-effects in the rest. Dose escalation was exclusively to
improve disease control. The overall response rate and disease control
rate was 80% (8/10) and 90% (9/10) in patients who did not require
dose adjustment; while the respective rates were 85.7% (6/7) and
100% (7/7) in patients who had dose reduction. The optimal dose of
afatinib defined by good disease control and tolerable side-effects was
50mg od in 9.1% (2/22), 40mg od in 31.8% (7/22), 30mg od in 31.8%
(7/22), 25mg od in 13.6% (3/22) and 20mg od in 13.6% (3/22) of
patients. Conclusion: We suggest starting afatinib at 30mg od and
adjust the dose accordingly because dose adjustment is not required in
most cases on this starting dose and it is the commonest optimal dose.
Keywords: afatinib, dose adjustment, Optimal dose
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Background: Clinical guidelines recommend routine testing for ge-
netic mutations in all adenocarcinoma of lung, including ALK EML4gene rearrangement. The coexistence of EGFR mutations and EML4-
ALK rearrangements have been described as extremely rare. Perhaps
this is due to its low prevalence and the sensitivity of available
diagnostic modalities. All India Institute of Medical Sciences, Bhu-
baneswar, is an upcoming institute of national importance situated
in eastern India. No report on EGFR mutation and EML4- ALK
rearrangement has been published so far from this region of India.
Method: We retrospectively analysed the available data of patients
from June 2014 to April 2018. Genetic testing was done from tissue
block specimens immediately after establishing the histology. EGFR
mutation analysis were done using commercially available Real Time
PCR and ALK-positivity was assessed with immunohistochemistry
(IHC) by VENTANA ALK (D5F3) CDx Assay. We investigated the
course of disease with the efficacy of targeted therapy in EGFR/ ALK
co-altered NSCLCs Result: Out of 251 NSCLC cases, 198 had
adenocarcinoma and only four patients (1.6%) had concomitant
EGFR/ALK co-alterations. Of the EGFR mutations, two were positive
for Exon 19 and other two were positive for Exon 21. Mean age for
Exon 19 and Exon 21 positive patients were 40 and 63 respectively.
All four patients were male and had advanced stages of lung cancer.
Mutation in all the four patients were detected from initial tissue
biopsy and they were negative for ROS1. Three patients had received
platinum based doublet regimen followed by EGFR-TKI and one
patient received Erlotinib. None had received Crizotinib yet.
Conclusion: The coexistence of EGFR mutations and EML4- ALK
rearrangements is low but higher than other geographical areas. Since
the two alterations may coexist from the beginning of diagnosis, future
perspective in management could be finding potential efficacy of a
double inhibition of both ALK and EGFR mutations. Keywords: EGFR,
ALK, NSCLC
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A Retrospective Study: Central Nervous System
Response to Osimertinib in Patients with Advanced
NSCLCY. Mu, P. Xing, X. Hao, Y. Wang, J. Li National Cancer Center/cancer
Hospital Chinese Academy of Medical Sciences and Peking Union Medical
College, Beijing/CN
Background: Central nervous system (CNS) metastases are common
in patients with non-small-cell lung cancer (NSCLC). More than 30%
of patients who progress during or after treatment with epidermal
growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have
CNS metastases. Osimertinib, a third-generation EGFR-TKI, has been
demonstrated promising intracranial efficacy in patients with
advanced NSCLC from several large scale randomized control trials.
We aimed to explore clinical impact of osimertinib for patients with
CNS metastases, advanced NSCLC in real world setting. Method:
Patients with advanced NSCLC who received osimertinib after pro-
gression of prior EGFR-TKIs and CNS metastases on baseline brain scan
were retrospectively collected from Cancer Hospital Chinese Academy
of Medical Sciences. Primary outcome was objective response rate
(ORR) and secondary objectives were disease control rate (DCR),
progression-free survival (PFS), time to tumor response, median best
percentage change from baseline in CNS target lesion (TL) size and
safety. Result: Between Apr 1, 2017, and Dec 30, 2017, 22 patients met
selection criteria, 15 with 1 measurable CNS lesion (RECIST 1.1) were
